Compare Lockheed Martin Corporation (LMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Lockheed Martin Corporation trades at $505.59 (market cap $117.48B), while State Street SPDR S&P Biotech ETF trades at $153.7. The key difference: Lockheed Martin Corporation pays a 2.71% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lockheed Martin Corporation nearer its low. Which is the better fit depends on your goals.
| LMT | XBI | |
|---|---|---|
Market Cap | $117.48B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $676.70 | $164.28 |
52-Week Low | $410.74 | $85.16 |
Enterprise Value | $136.28B | — |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.44, showing modest daily gains of 0.13%. The stock faces bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though Q3 2025 exceeded expectations. Revenue growth remains steady, reaching $75.05B in 2025, while net margins have compressed to 6.38%. Analyst sentiment is strongly positive with 57% buy ratings and a $614 consensus target, supported by recent contract wins and new product launches like the PAC-3 ACE interceptor.
LMT offers defensive exposure to elevated defense spending with a $194B backlog, but faces execution risks from margin pressure and debt levels. The stock trades at a premium 24.6x P/E with technical weakness near support at $504. Upside depends on Q2 earnings beat and defense budget sustainability amid geopolitical tensions.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
